New AI-Powered Free Company Valuation tool for any company in the world. Upload a PDF financial statement to receive an instant report with customizable forecasts, credit score, default probability and key financial metrics. Try Now for Free →
- Get an AI-powered company valuation or credit risk report in just 2 minutes
- Get reports of any company in the world with a financial statement in any language
- Upload a PDF financial statement to receive an instant report with customizable forecasts, credit score, default probability and key financial metrics
Ascendis Pharma Oncology Division A/S — Credit Rating and Financial Key Figures
Credit rating
Company information
About Ascendis Pharma Oncology Division A/S
Ascendis Pharma Oncology Division A/S (CVR number: 41034076) is a company from GENTOFTE. The company recorded a gross profit of -85226 kEUR in 2025. The operating profit was -85.3 mEUR, while net earnings were -110.1 mEUR. The profitability of the company measured by Return on Assets (ROA) was -19.1 %, which can be considered poor and Return on Equity (ROE) was -222486.9 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -100 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Ascendis Pharma Oncology Division A/S's liquidity measured by quick ratio was 0 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.
Financial information
See financialsGross profit (kEUR)
EBIT (kEUR)
Profitability
Solidity
Key figures (kEUR)
See financials2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Volume | |||||
| Net sales | |||||
| Gross profit | -46 676.71 | -62 367.39 | - 140 146.00 | -92 475.00 | -85 226.00 |
| EBIT | -46 763.20 | -62 458.51 | - 140 193.00 | -92 552.00 | -85 274.00 |
| Net earnings | -47 980.23 | -64 912.25 | - 144 110.00 | - 106 375.00 | - 110 131.00 |
| Shareholders equity total | -76 108.65 | - 141 020.90 | - 285 131.00 | - 391 506.00 | - 501 637.00 |
| Balance sheet total (assets) | 5 608.14 | 5 604.08 | 457.00 | 99.00 | |
| Net debt | 81 259.78 | 146 130.56 | 285 134.00 | 391 492.00 | 501 629.00 |
| Profitability | |||||
| EBIT-% | |||||
| ROA | -79.0 % | -54.7 % | -64.6 % | -27.1 % | -19.1 % |
| ROE | -681.7 % | -1157.9 % | -4755.3 % | -38264.4 % | -222486.9 % |
| ROI | -80.8 % | -54.7 % | -64.6 % | -27.1 % | -19.1 % |
| Economic value added (EVA) | -46 953.53 | -62 662.98 | - 140 251.38 | -92 236.28 | -77 609.43 |
| Solvency | |||||
| Equity ratio | -93.1 % | -96.2 % | -99.8 % | -100.0 % | -100.0 % |
| Gearing | -107.4 % | -104.0 % | -100.2 % | -100.0 % | -100.0 % |
| Relative net indebtedness % | |||||
| Liquidity | |||||
| Quick ratio | 404.5 | 352.4 | 38.1 | 7.1 | |
| Current ratio | 404.5 | 352.4 | 38.1 | 7.1 | |
| Cash and cash equivalents | 449.65 | 478.52 | 442.00 | 99.00 | |
| Capital use efficiency | |||||
| Trade debtors turnover (days) | |||||
| Net working capital % | |||||
| Credit risk | |||||
| Credit rating | B | B | B | B | B |
Variable visualization
Roles
Companies in the same industry
- Company information
- Financial data
- Credit risk data
- All 400,000+ Danish companies
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.